Shukra Pharmaceuticals saw its shares climb more than 2% after the company confirmed that it has received an official Authorization Letter dated December 3, 2025, from Integra Medical Devices India Private Limited. As of 10:05 AM, the shares were trading 2.55% higher at Rs 39.34.
The approval marks a major milestone for the company as it has now been appointed as the Authorized Distributor for all medical equipment and device purchases made under the Directorate General Armed Forces Medical Services (DGAFMS) across India.
This new authorization places Shukra Pharmaceuticals at the centre of procurement activities for medical devices intended for defence hospitals, command units and other establishments functioning under DGAFMS. With this designation, the company will take charge of promoting, marketing and supplying the complete range of products manufactured and supplied by Integra Medical Devices India. All DGAFMS-related procurement initiated after the issuance of this authorization will be routed through Shukra Pharma, making the company a key distribution partner for the defence medical ecosystem.
The arrangement also requires Shukra Pharma to work closely with Integra Lifesciences to ensure smooth coordination on every project. Both companies will adhere to mutually agreed commercial terms, strict compliance standards and ethical business practices, reflecting the high level of oversight required in defence-related medical procurement.
The authorization is valid through December 31, 2026, unless it is ended earlier under the terms outlined in the letter.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
